Human-pharmacological investigations on the platelet adhesiveness- and aggregation-inhibiting effect of EMD 26 644, an oxazolyl-thio-propionic acid derivate.
EMD 26 644, a compound of novel chemical structure and with platelet aggregation-inhibiting properties, was investigated in 2 controlled clinical pharmacological studies involving 42 normal volunteers. In the first study with 22 subjects exhibiting normal or spontaneously increased platelet aggregation the influence of 1 X 250 mg EMD 26 644 p.o. on the platelet aggregation and adhesiveness was examined ex vivo. In the second study 20 subjects with and without a premedication of 1 X 250 mg EMD 26 644 were exposed an artificial climate with special platelet-irritating properties. A single oral dose of 250 mg EMD 26 644 markedly and significantly inhibited the platelet aggregation and adhesiveness over a period of several days.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001772:Blood Cell Count; D001792:Blood Platelets / Q000187:drug effects; D055590:Electromagnetic Phenomena; D006801:Humans; D066298:In Vitro Techniques; D010080:Oxazoles / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D011422:Propionates / Q000494:pharmacology*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D010080:Oxazoles; D011422:Propionates; C016869:tioxaprofen